The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein–1 in patients with type 2 diabetes complicated by hyperlipidemia

Takebayashi, Kohzo; Matsumoto, Sachiko; Wakabayashi, Shigeo; Inukai, Yoshihisa; Matsutomo, Rika; Aso, Yoshimasa; Iwamoto, Toshihiko

doi:10.1016/j.metabol.2005.04.008

Cited by 19 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a clinical report, 26 low-dose atorvastatin significantly decreased serum MCP-1. Lovastatin and simvastatin inhibited MCP-1 production in a dose-dependent manner in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 89%

Inhibition of Laser-Induced Choroidal Neovascularization by Atorvastatin by Downregulation of Monocyte Chemotactic Protein-1 Synthesis in Mice

Yamada

Sakurai

Itaya

et al. 2007

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…In a clinical report, 26 low-dose atorvastatin significantly decreased serum MCP-1. Lovastatin and simvastatin inhibited MCP-1 production in a dose-dependent manner in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 89%

Inhibition of Laser-Induced Choroidal Neovascularization by Atorvastatin by Downregulation of Monocyte Chemotactic Protein-1 Synthesis in Mice

Yamada

Sakurai

Itaya

et al. 2007

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…Clinical studies have shown conflicting data regarding the effect of statins on serum levels of MCP-1 [3][4][5][6]. We investigated the influence of simvastatin on the acute phase proteins C-reactive protein (CRP) and serum amyloid A (SAA) and the cytokines MCP-1, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and macrophage colony stimulating factor (MCSF) in patients with hypercholesterolaemia.…”

mentioning

confidence: 99%

Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1

Rallidis

Hamodraka

Fountoulaki

et al. 2008

International Journal of Cardiology

View full text Add to dashboard Cite

“…MCP‐1 is often considered as responsible for accumulation of macrophages in adipose tissue (Westerbacka et al ., ), however, contradicted by other studies (Inouye et al ., ). MCP‐1 signalling is also implicated in development of obesity (Younce et al ., ), and lowering of MCP‐1 level is correlated with effective control of MetS (Takebayashi et al ., ).…”

Section: Discussionmentioning

confidence: 99%

“…MCP-1 is often considered as responsible for accumulation of macrophages in adipose tissue (Westerbacka et al, 2008), however, contradicted by other studies (Inouye et al, 2007). MCP-1 signalling is also implicated in development of obesity (Younce et al, 2009), and lowering of MCP-1 level is correlated with effective control of MetS (Takebayashi et al, 2005). Several genetic association studies reported association with MCP-1 gene polymorphism with obesity, diabetes and individual risk factors of MetS (Simeoni et al, 2004;Kouyama et al, 2008;Szalai et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

Monocyte chemoattractant protein‐1 gene polymorphism and its serum level have an impact on anthropometric and biochemical risk factors of metabolic syndrome in Indian population

Madeshiya

Singh

Dwivedi

et al. 2015

Int J Immunogenetics

View full text Add to dashboard Cite

Monocyte chemoattractant protein-1 (MCP-1), encoded by gene CCL-2 (Chemokine C-C motif 2), is the ligand of chemokine receptor CCR-2. Concurrent clinical alteration in several metabolic aspects, including central obesity, dysglycemia, dyslipidemia and hypertension, is clinically characterized as metabolic syndrome (MetS). Role of MCP-1 in each of these aspects has been established in vitro and in animal studies as well. We here report genetic association of -2518 A>G MCP-1 (rs 1024611) gene polymorphism and level of MCP-1 with MetS in North Indian subjects. We analysed (n=386, controls and n=384, MetS subjects) for MCP-1 gene polymorphism using PCR-RFLP, its serum level using ELISA, anthropometric (body mass index, waist and hip circumferences, waist-hip ratio and blood pressure) and biochemical (serum lipids, plasma glucose and insulin levels) variables in a genetic association study. The body mass index, waist circumference, hip circumference, waist-hip ratio, blood pressure, serum lipids, insulin and fasting plasma glucose level were significantly high in MetS subjects. Regression analysis showed significant correlation of body mass index, waist and hip circumference, systolic/diastolic blood pressure, fasting glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein fasting insulin and HOMA-IR with MetS. MCP-1 allele and genotype were significantly associated with MetS. Serum MCP-1 level was high in overall cases. In conclusions, the MCP-1 2518A>G (rs 1024611) polymorphism has significant impact on risk of MetS, and MCP-1 level correlates with anthropometric and biochemical risk factors of MetS.

show abstract

The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein–1 in patients with type 2 diabetes complicated by hyperlipidemia

Cited by 19 publications

References 23 publications

Inhibition of Laser-Induced Choroidal Neovascularization by Atorvastatin by Downregulation of Monocyte Chemotactic Protein-1 Synthesis in Mice

Inhibition of Laser-Induced Choroidal Neovascularization by Atorvastatin by Downregulation of Monocyte Chemotactic Protein-1 Synthesis in Mice

Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1

Monocyte chemoattractant protein‐1 gene polymorphism and its serum level have an impact on anthropometric and biochemical risk factors of metabolic syndrome in Indian population

Contact Info

Product

Resources

About